Crispr Therapeutics (CRSP) Rating Reiterated by Oppenheimer – The Lincolnian Online
The Lincolnian Online |
Crispr Therapeutics (CRSP) Rating Reiterated by Oppenheimer
The Lincolnian Online Crispr Therapeutics (NASDAQ:CRSP)’s stock had its “hold” rating reiterated by Oppenheimer in a report issued on Thursday. A number of other brokerages also recently weighed in on CRSP. BidaskClub downgraded Crispr Therapeutics from a “buy” rating to a … Cann Reaffirms “Hold” Rating for Crispr Therapeutics (NASDAQ …StockNewsTimes Crispr Therapeutics AG (CRSP) Insider Tyler Dylan-Hyde Sells …Dispatch Tribunal |
Motherboard |
Some Farmers Still Don’t Trust CRISPR, Thanks to GMOs
Motherboard One way CRISPR could help is by speeding up the breeding process. Unlike GMOs, where a foreign gene is inserted into the crop to create a change, with CRISPR, researchers can make small changes in the native DNA that could also occur there in nature … |
Dispatch Tribunal |
Tyler Dylan-Hyde Sells 15000 Shares of Crispr Therapeutics AG (CRSP) Stock
The Ledger Gazette Crispr Therapeutics logo Crispr Therapeutics AG (NASDAQ:CRSP) insider Tyler Dylan-Hyde sold 15,000 shares of Crispr Therapeutics stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $18.90, for a … Crispr Therapeutics’ (CRSP) Hold Rating Reiterated at CannThe Lincolnian Online Crispr Therapeutics (NASDAQ:CRSP) Research Coverage Started at OppenheimerStockNewsTimes A Look at 2 Trending Stocks: CRISPR Therapeutics AG (CRSP), Athersys, Inc. (ATHX)Post Analyst Dispatch Tribunal all 14 news articles » |
Dispatch Tribunal |
Tyler Dylan-Hyde Sells 15000 Shares of Crispr Therapeutics AG (CRSP) Stock
The Ledger Gazette Crispr Therapeutics logo Crispr Therapeutics AG (NASDAQ:CRSP) insider Tyler Dylan-Hyde sold 15,000 shares of Crispr Therapeutics stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $18.90, for a … Crispr Therapeutics’ (CRSP) Hold Rating Reiterated at CannThe Lincolnian Online Crispr Therapeutics (NASDAQ:CRSP) Research Coverage Started at OppenheimerStockNewsTimes A Look at 2 Trending Stocks: CRISPR Therapeutics AG (CRSP), Athersys, Inc. (ATHX)Post Analyst Dispatch Tribunal all 14 news articles » |